Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133932) titled 'A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older' on Oct. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Jiangsu Provincial Center for Disease Control and Prevention
Condition:
RSV primarily causes acute lower respiratory tract infections (ALRTI), with common symptoms including cough, sputum production, wheezing and shortness of breath, fever, and abnormal breath sounds. Severe cases may present with asthma syndrome,...